
Celiac disease affects between 2 to 13 per 100,000 and may appear at any time in a person's life. It is an inheritable autoimmune disorder that increases the risk of gastrointestinal cancer and is hallmarked by malabsorption, resulting in diarrhea and malnutrition. Classical symptoms include abdominal pain, flatulence, bloating and chronic diarrhea or constipation (or both). If Celiac disease is left untreated, it can become life-threatening.
Celiac disease mainly develops in people who have a genetic susceptibility. An immunologic reaction to the ingestion of gluten (proteins found in all forms of wheat and related grains) damages the intestinal villi and the mucosal surface of the small intestine. Damaged villi no longer effectively absorb basic nutrients, causing an increased risk of associated disorders such as osteoporosis, and vitamin and mineral deficiencies.
The only treatment for Celiac disease is lifelong adherence to a gluten-free diet.
ActoGeniX has already obtained promising initial efficacy data for the effect of ActoBiotics™ in a preclinical Celiac disease model, rendering tolerance to gluten.